Besides the main objective, there are 3 other objectives as follows:~To determine dose-limiting toxicity (DLT) of HM781-36B~To characterize the pharmacokinetics of HM781-36B, following oral administration of HM781-36B~To evaluate anticancer activity of HM781-36B in patients with advanced solid malignancies Groups of 3 patients per cohort or dose level will be treated with escalating doses of HM781-36B
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B.